Clene

Clene Nanomedicine is a Utah based biopharmaceutical company that develops and commercializes therapeutics for the treatment of neurodegenerative diseases. Read more

Rob Etherington's photo - President & CEO of Clene

President & CEO

Rob Etherington

CEO Approval Rating

70/100

Founded:

2013

Status:

PublicMerged with Tottenham Acquisition I LimitedNASDAQCLNN

CLENE TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Cognition Therapeutics is one of Clene's top competitors. Cognition Therapeutics was founded in 2007, and its headquarters is in Pittsburgh, Pennsylvania. Like Clene, Cognition Therapeutics also works within the Pharmaceuticals sector. Cognition Therapeutics has 33 fewer employees than Clene.

Aquinnah is Clene's #2 rival. Aquinnah was founded in 2014 in Cambridge, Massachusetts. Aquinnah operates in the Pharmaceuticals industry. Aquinnah generates $3.7M more revenue than Clene.

Verge Genomics is a top competitor of Clene. Verge Genomics is a Private company that was founded in South San Francisco, California in 2015. Verge Genomics is in the Biotechnology field. Verge Genomics has 28 fewer employees vs. Clene.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Alector a competitor of Clene?

Clene Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$ < 1M

Clene's revenue is the ranked 20th among it's top 10 competitors. The top 10 competitors average 114.9M. Over the last two quarters, Clene's revenue has grown by 204.3%. Specifically, in Q1 2021's revenue was $ < 1M; in Q1 2020, it was $ < 1M.

Clene Acquisitions

No recent acquisitions found related to Clene

Clene Funding History

Since Clene was founded in 2013, it has participated in 8 rounds of funding. In total Clene has raised $60.0M. Clene's last funding round was on May 2021 for a total of $9.2M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Post-IPO Equity
May 2021
$9.3M
-
IPO SPAC
Dec 2020
--
-
Series D
Aug 2020
$42.5M
-
Debt
Jul 2020
$6.1M
Debt - PPP (CARES Act)
Apr 2020
$350K - $1M

Since Clene was founded in 2013, it has participated in 8 rounds of funding. In total Clene has raised $60.0M. Clene's last funding round was on May 2021 for a total of $9.2M

Clene Investments

No recent investments found related to Clene

Clene News

April 30, 2021GlobeNewswire

Clene Nanomedicine Receives Two Patent Notice of Allowances in the U.S. for Its Platform Nanocrystal Therapeutic Technology

SALT LAKE CITY, April 30, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidia... See more »
April 14, 2021MarketScreener

SEC Filing (3/A)

(marketscreener.com) SEC FORM 3/ASEC Form 3 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION W... See more »
March 29, 2021BioSpace

Clene Reports Full Year 2020 Operating and Financial Highlights - Mar 29, 2021

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutic... See more »
March 10, 2021Benzinga

Clene Nanomedicine Announces Upcoming Presentations at the Maxim Group LLC Inaugural 2021 Emerging Growth Virtual Conference and Launch of Clene Spotlight Webpage on M Vest LLC

SALT LAKE CITY, March 10, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiar... See more »
March 9, 2021Markets Insider

Clene Nanomedicine Announces Achievement of 50% Enrollment in the Phase 3 HEALEY ALS Platform Trial

SALT LAKE CITY, March 09, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidia... See more »
March 3, 2021Markets Insider

Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences

SALT LAKE CITY, March 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidia... See more »
February 25, 2021Benzinga

Clene's Lead Candidate Shows Improvement In Functional Scores In Multiple Sclerosis Studies

Clene Inc (NASDAQ: CLNN) has reported updated blinded interim data from the VISIONARY-MS Phase 2 stud... See more »

Clene Press Releases

March 17, 2021StreetInsider

CLNN) Featured in Virtual Coverage of the 33rd Annual ROTH Conference

Clene Inc. (NASDAQ: CLNN), a clinical-stage biopharmaceutical company focused on neurodegenerative di... See more »
March 1, 2021GlobalNewswire

Clene Nanomedicine Awarded Michael J. Fox Foundation Grant to Accelerate the Development of CNM-Au8 as a Treatment for Parkinson's Disease

SALT LAKE CITY, March 01, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidia... See more »
January 20, 2021GlobeNewswire

Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis

SALT LAKE CITY, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiar... See more »
September 11, 2020PR Newswire

Clene Nanomedicine Presents Updated Blinded Interim Data from the VISIONARY-MS Phase 2 Study

SALT LAKE CITY, Sept. 11, 2020 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmace... See more »
February 11, 2020StreetInsider

Clene Nanomedicine Publishes Results Demonstrating Preclinical Efficacy of CNM-Au8 Gold Nanocrystals for Remyelination in Multiple Sclerosis in Scientific Reports

SALT LAKE CITY, Feb. 11, 2020 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceu... See more »
December 3, 2019PR Newswire

Clene Nanomedicine Announces First Patient Enrolled in the REPAIR-PD Clinical Trial for the Treatment of Parkinson's Disease with the Nanocatalytic Therapeutic, CNM-Au8

SALT LAKE CITY, Dec. 3, 2019 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceut... See more »

Social Media

Clene Headquarters

6550 South Millrock Drive Suite G50

Salt Lake City, Utah84121

801-676-9695

Driving Directions »

Trending Companies

Clene Summary

ABOUT

Overview

Clene Nanomedicine is a Utah based biopharmaceutical company that develops and commercializes therapeutics for the treatment of neurodegenerative diseases. Clene was founded in 2013. Clene's headquarters is located in Salt Lake City, Utah, USA 84121. ...

CEO

Clene's President & CEO, Rob Etherington, currently has an approval rating of 70%. Clene's primary competitors are Cognition Therapeutics, Aquinnah & Verge Genomics.

Website

clene.com

Frequently Asked Questions about Clene

  1. When was Clene founded?

    Clene was founded in 2013
  2. Who is Clene's CEO?

    Clene's CEO is Rob Etherington
  3. How much revenue does Clene generate?

    Clene generates $ < 1M in revenue
  4. How much funding does Clene have?

    Clene has historically raised $60M in funding
  1. Where is Clene's headquarters?

    Clene's headquarters is in Salt Lake City Utah, USA
  2. How many employees does Clene have?

    Clene has 63 employees
  3. What sector does Clene operate in?

    Clene is in Pharmaceuticals
  4. Who are Clene's competitors?

    Clene's top competitors are Cognition Therapeutics, Aquinnah, Verge Genomics